Cargando…

Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants

Combining bioinformatics and in vitro cytology assays, a predictive method was established to quickly evaluate the protective effect of immunity acquired through SARS-CoV-2 infection against variants. Bioinformatics software was first used to predict the changes in the affinity of variant antigens t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yajuan, Xiong, Husheng, Liu, Shuang, Wu, Dawei, Zhang, Xiaomin, Shi, Xiaolu, Qu, Jing, Chen, Long, Liu, Zheng, Peng, Bo, Zhang, Dingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386485/
https://www.ncbi.nlm.nih.gov/pubmed/37515251
http://dx.doi.org/10.3390/v15071565
_version_ 1785081676815138816
author Zhu, Yajuan
Xiong, Husheng
Liu, Shuang
Wu, Dawei
Zhang, Xiaomin
Shi, Xiaolu
Qu, Jing
Chen, Long
Liu, Zheng
Peng, Bo
Zhang, Dingmei
author_facet Zhu, Yajuan
Xiong, Husheng
Liu, Shuang
Wu, Dawei
Zhang, Xiaomin
Shi, Xiaolu
Qu, Jing
Chen, Long
Liu, Zheng
Peng, Bo
Zhang, Dingmei
author_sort Zhu, Yajuan
collection PubMed
description Combining bioinformatics and in vitro cytology assays, a predictive method was established to quickly evaluate the protective effect of immunity acquired through SARS-CoV-2 infection against variants. Bioinformatics software was first used to predict the changes in the affinity of variant antigens to the CV30 monoclonal antibody by integrating bioinformatics and cytology assays. Then, the ability of the antibody to neutralize the variant antigen was further verified, and the ability of the CV30 to neutralize the new variant strain was predicted through pseudovirus neutralization experiments. The current study has demonstrated that when the Molecular Operating Environment (MOE) predicts |ΔBFE| ≤ 3.0003, it suggests that the CV30 monoclonal antibody exhibits some affinity toward the variant strain and can potentially neutralize it. However, if |ΔBFE| ≥ 4.1539, the CV30 monoclonal antibody does not display any affinity for the variant strain and cannot neutralize it. In contrast, if 3.0003 < |ΔBFE| < 4.1539, it is necessary to conduct a series of neutralization tests promptly with the CV30 monoclonal antibody and the variant pseudovirus to obtain results and supplement the existing method, which is faster than the typical procedures. This approach allows for a rapid assessment of the protective efficacy of natural immunity gained through SARS-CoV-2 infection against variants.
format Online
Article
Text
id pubmed-10386485
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103864852023-07-30 Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants Zhu, Yajuan Xiong, Husheng Liu, Shuang Wu, Dawei Zhang, Xiaomin Shi, Xiaolu Qu, Jing Chen, Long Liu, Zheng Peng, Bo Zhang, Dingmei Viruses Article Combining bioinformatics and in vitro cytology assays, a predictive method was established to quickly evaluate the protective effect of immunity acquired through SARS-CoV-2 infection against variants. Bioinformatics software was first used to predict the changes in the affinity of variant antigens to the CV30 monoclonal antibody by integrating bioinformatics and cytology assays. Then, the ability of the antibody to neutralize the variant antigen was further verified, and the ability of the CV30 to neutralize the new variant strain was predicted through pseudovirus neutralization experiments. The current study has demonstrated that when the Molecular Operating Environment (MOE) predicts |ΔBFE| ≤ 3.0003, it suggests that the CV30 monoclonal antibody exhibits some affinity toward the variant strain and can potentially neutralize it. However, if |ΔBFE| ≥ 4.1539, the CV30 monoclonal antibody does not display any affinity for the variant strain and cannot neutralize it. In contrast, if 3.0003 < |ΔBFE| < 4.1539, it is necessary to conduct a series of neutralization tests promptly with the CV30 monoclonal antibody and the variant pseudovirus to obtain results and supplement the existing method, which is faster than the typical procedures. This approach allows for a rapid assessment of the protective efficacy of natural immunity gained through SARS-CoV-2 infection against variants. MDPI 2023-07-17 /pmc/articles/PMC10386485/ /pubmed/37515251 http://dx.doi.org/10.3390/v15071565 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhu, Yajuan
Xiong, Husheng
Liu, Shuang
Wu, Dawei
Zhang, Xiaomin
Shi, Xiaolu
Qu, Jing
Chen, Long
Liu, Zheng
Peng, Bo
Zhang, Dingmei
Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
title Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
title_full Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
title_fullStr Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
title_full_unstemmed Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
title_short Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
title_sort combining moe bioinformatics analysis and in vitro pseudovirus neutralization assays to predict the neutralizing ability of cv30 monoclonal antibody on sars-cov-2 variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386485/
https://www.ncbi.nlm.nih.gov/pubmed/37515251
http://dx.doi.org/10.3390/v15071565
work_keys_str_mv AT zhuyajuan combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT xionghusheng combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT liushuang combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT wudawei combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT zhangxiaomin combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT shixiaolu combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT qujing combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT chenlong combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT liuzheng combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT pengbo combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants
AT zhangdingmei combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants